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ABSTRACT
Carbamazepine (CBZ), oxcarbazepine (OXC),
and eslicarbazepine acetate (ESL) belong to the
dibenzazepine family of antiepileptic drugs and
are all thought to primarily act as sodium
channel blockers (SCBs). However, ESL is struc-
turally distinct from CBZ and OXC, resulting in
differences in metabolism, pharmacokinetics,
and pharmacodynamics. Despite a lack of direct
comparative data, evidence for potential differ-
ences in effectiveness and tolerability within
the dibenzazepine family has emerged from
studies in which patients being treated with one
dibenzazepine agent have received adjunctive
treatment with another (having achieved
insufficient seizure control with the first) or
have transitioned from one dibenzazepine
agent to another because of lack of effectiveness
or poor tolerability. Most of these studies have
been conducted in the real-world clinical prac-
tice setting. ESL has been shown to be effective
as adjunctive therapy in patients who have
previously achieved inadequate seizure control
with CBZ, indicating that the use of different
dibenzazepine agents in combination can pro-
vide additive effectiveness benefits, which may
reflect underlying differences in their mecha-
nisms of action. Similarly, ESL monotherapy
can be effective in patients who have switched
from another dibenzazepine, such as CBZ or
OXC, because of inadequate efficacy. There is
also considerable evidence to demonstrate that
patients transitioning from OXC or CBZ to ESL
as a result of adverse events experience
improvements in tolerability, which may also
be associated with improvements in quality of
life, alertness, and/or lipid profiles. Current
evidence therefore demonstrates that ESL differs
from other dibenzazepine agents in terms of
effectiveness and tolerability.
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INTRODUCTION
Sodium channel blockers (SCBs) have played a
central role in the pharmacological manage-
ment of focal and generalized tonic–clonic
seizures since phenytoin was first used as an
antiepileptic drug (AED) in 1936 [1]. In addition
to phenytoin, AEDs that are primarily SCBs in
their mechanism of action include lamotrigine
(LTG), lacosamide, rufinamide, and the diben-
zazepine carboxamide family of AEDs, com-
prising carbamazepine (CBZ), oxcarbazepine
(OXC), and eslicarbazepine acetate (ESL) [1].
Despite sharing a common mechanistic target—
the voltage-gated sodium channel—SCBs differ
in their specific mechanisms of action. For
example, phenytoin, CBZ, and OXC are
thought to block the fast inactivation of sodium
channels, whereas lacosamide and ESL are
thought to act on the slow inactivated state of
sodium channels [1–3]. Such mechanistic vari-
ations may underlie the observed differences in
efficacy of SCBs, and help to explain why SCBs
may show additive effects when used in com-
bination, compared with when used as single
agents alone [1]. Furthermore, SCBs differ
markedly from each other in their tolerability/
safety profiles, particularly in terms of their
variable propensity for enzyme induction [1, 4].
The objective of this article is to review cur-
rent evidence for differences in effectiveness
and tolerability between ESL and other agents
within the dibenzazepine family of AEDs, and
to discuss the implications of these differences
in clinical practice. This article is based on pre-
viously conducted studies. All procedures per-
formed in studies conducted by the authors
involving human participants were in accor-
dance with the ethical standards of the institu-
tional and/or national research committee and
with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards;
informed consent was obtained from all indi-
vidual participants included in these studies.
The article also contains studies with human
participants or animals that were not performed
by any of the authors.
OVERVIEW OF THE DIBENZAZEPINE
FAMILY
CBZ was discovered by chance in the 1950s
[5, 6] and, over subsequent decades, became
widely accepted as the first drug of choice for
focal epilepsy [7] and the standard comparator
for European regulatory studies in newly diag-
nosed epilepsy [1]. OXC, a keto analogue of CBZ
[8], was introduced in the 1980s, with the aim
of improving the pharmacokinetic profile and
tolerability of CBZ [6]. In the 1990s, esters of its
major metabolite were synthesized in order to
provide further improvements in pharmaco-
kinetics and tolerability, which resulted in the
development of ESL [6, 9].
Pharmacology and Potential Clinical
Correlates
CBZ, OXC, and ESL all have a dibenzazepine
nucleus bearing the 5-carboxamide substitute,
but ESL is structurally distinct from CBZ and
OXC at the 10,11-position (Fig. 1) [10, 11],
resulting in differences in metabolism, phar-
macokinetics, and pharmacodynamics (Table 1)
[15]. Unlike CBZ, ESL is not metabolized to
carbamazepine-10,11-epoxide, the metabolite
which may play a major role in causing adverse
effects, such as drowsiness, dizziness, and
diplopia [6, 9, 16, 17]. CBZ’s tolerability is fur-
ther affected by its potent enzyme induction
properties, which reduce the duration and
action of many drugs [4] and may additionally
contribute to the development of comorbidi-
ties, including vascular disease, osteoporosis,
and sexual dysfunction, via effects on enzymes
involved in endogenous metabolic pathways
[4, 18].
ESL’s metabolism also differs from that of
OXC. OXC rapidly undergoes hydroxylation to
an active 10-monohydroxy derivative, com-
prising an enantiomeric mixture of (S)-licar-
bazepine (‘‘eslicarbazepine’’) and (R)-
licarbazepine (in a ratio of 4:1), with a small
amount of parent compound remaining in the
plasma [8, 11, 19]. ESL is stereoselectively
metabolized primarily to (S)-licarbazepine,
which accounts for approximately 94% of
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plasma drug exposure following oral adminis-
tration of ESL, with (R)-licarbazepine and
oxcarbazepine accounting for approximately
5% and less than 1%, respectively (ratio of
(S)-licarbazepine to (R)-licarbazepine, approxi-
mately 19:1; Fig. 1) [11, 19]. Importantly, this
stereoselective metabolism of ESL avoids the
early peaks in (R)-licarbazepine and OXC
Fig. 1 Chemical structure and main metabolic pathways
of CBZ, OXC, and ESL. CBZ carbamazepine, ESL
eslicarbazepine acetate, OXC oxcarbazepine. Reprinted by
permission from Springer Nature, Neurotherapeutics
(Eslicarbazepine acetate (BIA 2-093)), Luis Almeida,
Patrı´cio Soares-da-Silva, 2007
Table 1 Summary comparison of metabolism, pharmacokinetics, and pharmacodynamics of CBZ, OXC, and ESL
[3, 11–14]
CBZ OXC ESL
Metabolism
Route Hepatic Hepatic Hepatic
Primary
biotransformation
pathway
Epoxide biotransformation to
CBZ 10,11-epoxide
Cytosolic reduction to
10-monohydroxy derivative
Hydrolysis to (S)-licarbazepine
Pharmacokinetics
Time to maximum
plasma concentration
12 h 4.5 h 2–3 h
Time to steady state 1–2 weeks 2–3 days 4–5 days
Half-life of active
metabolite
6 h 9.3 h 20–24 h
Pharmacodynamics
Main active metabolite CBZ 10,11-epoxide 10-Monohydroxy derivativea (S)-Licarbazepine
Primary mechanism of
action
Fast inactivation of voltage-
gated sodium channels
Fast inactivation of voltage-
gated sodium channels
Slow inactivation of voltage-
gated sodium channels
CBZ carbamazepine, ESL eslicarbazepine acetate, OXC oxcarbazepine
a An enantiomeric mixture of (S)-licarbazepine and (R)-licarbazepine in a ratio of 4:1
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concentrations observed in plasma and cere-
brospinal fluid following immediate-release
OXC administration, which are thought to be
associated with OXC-related side effects, such as
dizziness and headache [19]. Consequently, ESL
may be associated with fewer neurological/psy-
chiatric side effects than OXC [13, 14, 20].
Evidence from therapeutic drug monitoring
databases has demonstrated that ESL is associ-
ated with fewer interactions with other AEDs
than CBZ and OXC [21]. The pharmacokinetic
profile of ESL was shown to be unaffected by
enzyme-inducing AEDs and valproate, and ESL
did not affect the metabolism of LTG; by con-
trast, CBZ clearance was found to be increased
by enzyme-inducing AEDs and valproate, and
LTG clearance was increased by both OXC and
CBZ [21]. Furthermore, once-daily dosing of ESL
may improve the likelihood of adherence to ESL
treatment in comparison with CBZ and OXC,
since adherence to a once-daily AED dosing
regimen has been shown to be significantly
better than to a twice- or three-times daily
dosing regimen [22].
Pharmacodynamic Differences
ESL differs pharmacodynamically from CBZ,
since ESL is thought to act primarily by
enhancing the slow inactivation of voltage-
gated sodium channels, whereas CBZ is thought
to alter the fast inactivation of these channels
[3]. As previously mentioned, although OXC
and ESL share a common active metabolite (es-
licarbazepine), this accounts almost exclusively
for ESL’s pharmacodynamic effect, whereas it is
the monohydroxy derivative of OXC (compris-
ing a substantial proportion of (R)-licarbazepine
as well as eslicarbazepine) that accounts for its
pharmacodynamic effect (Fig. 1) [8, 11, 19]. The
apparent affinity of eslicarbazepine for voltage-
gated sodium channels in the inactivated and
resting states is considerably lower than that of
CBZ and (R)-licarbazepine, suggesting that esli-
carbazepine has enhanced selectivity for
inhibiting rapidly firing active ‘‘epileptic’’ neu-
rons [23–26]. This may in part explain the
observed efficacy of ESL in the presence of CBZ
resistance in experimental models of epilepsy,
which have demonstrated significant add-on
effects when ESL is used in combination with
CBZ [27, 28]. These pharmacodynamic differ-
ences are thought to influence the clinical
effectiveness and tolerability of the members of
the dibenzazepine family, CBZ, OXC, and ESL.
DIFFERENCES IN EFFECTIVENESS:
EVIDENCE FROM CLINICAL
STUDIES
Few clinical studies have directly compared the
efficacy and tolerability of members of the
dibenzazepine family. Results from the Stan-
dard And New Antiepileptic Drugs (SANAD)
study suggested a non-significant advantage for
CBZ compared with OXC [7]. ESL was not
included as it was not approved at the time
SANAD was conducted. In a phase III random-
ized controlled trial, ESL was shown to be non-
inferior to controlled-release CBZ (CBZ-CR) as
monotherapy for patients with newly diagnosed
focal epilepsy [29]. Seizure freedom rates during
the entire 6-month evaluation period for the
per protocol population (the primary endpoint
of the trial) were 71.1% with ESL and 75.6%
with CBZ-CR [29].
Despite the lack of direct comparative data,
evidence for potential differences in effective-
ness (and tolerability) within the dibenzazepine
family has emerged from studies in which
patients have received adjunctive treatment
with a dibenzazepine AED. These patients had
achieved insufficient seizure control with
another AED, or were transitioned from one
dibenzazepine agent to another, because of lack
of effectiveness or poor tolerability. The major-
ity of this evidence—as outlined below—has
emerged from the real-world setting, high-
lighting the importance of clinical practice
studies in further complementing evidence
obtained from clinical trials.
A post hoc analysis was conducted of 1049
patients enrolled in three phase III, multicenter,
double-blind, randomized, placebo-controlled
trials, in which adults with focal seizures,
despite treatment with one to three AEDs,
received adjunctive treatment with ESL [30].
Efficacy was compared between patients who
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did (n = 611) and did not (n = 438) receive CBZ
as a concomitant AED [30]. Seizure frequency
over a 12-week maintenance period (the pri-
mary endpoint) was significantly reduced,
compared with placebo, in patients treated with
ESL 800 and 1200 mg/day, not only when
administered without CBZ (p\0.01 and
p\0.05, respectively) but, interestingly, also
when administered with CBZ (p\0.01 and
p\0.0001, respectively) [30]. In patients not
receiving CBZ, responder rates (response
defined as at least 50% seizure frequency
reduction) were 26% with placebo, 39% with
ESL 800 mg/day, and 40% with 1200 mg/day
(Fig. 2) [30]. In those receiving CBZ, responder
rates were 19% with placebo, 34% with ESL
800 mg/day and 47% with ESL 1200 mg/day
(Fig. 2) [30]. These data suggest that ESL was
efficacious in both subsets of patients, with or
without concomitant CBZ. Patients who did not
achieve seizure control with CBZ may still
benefit from either switching to or adding in
adjunctive ESL.
These findings are supported by the results of
real-world clinical practice studies. The ESLI-
BASE study was a 1-year, multicenter, retro-
spective, non-interventional study, which
evaluated the long-term efficacy and safety of
adjunctive ESL therapy in 327 patients with
focal epilepsy in a clinical practice setting in
Spain [31]. Sixty patients included in the ESLI-
BASE study were being treated with CBZ at the
start of the study [31]. Of these, 45 were tran-
sitioned from CBZ to ESL (because of lack of
efficacy [n = 28] and tolerability problems
[n = 17] with CBZ; CBZ to ESL ratio, 1:1.5) and
15 were treated with both AEDs [31]. Among
those who transitioned from CBZ to ESL
(n = 45), 13.3% were seizure free during the
3 months prior to inclusion [31]. After
12 months of ESL treatment, 11.4% of patients
were seizure free, 38.7% had responded to ESL
treatment (response defined as at least 50%
seizure frequency reduction from baseline), and
20.0% had experienced worsening of seizures
[31]. Similarly, 50 patients were receiving OXC
before the start of the study, of whom 48 were
transitioned to ESL (because of adverse events
[AEs; n = 26] and lack of efficacy [n = 22]; OXC
to ESL ratio, 1:1) and two were treated with both
AEDs. Among patients who transitioned from
OXC to ESL (n = 48), 16.7% were seizure free in
the 3 months prior to inclusion [31]. After
12 months of ESL treatment, 31.3% were seizure
free, 45.9% were responders, and 16.7% had
experienced worsening of seizures [31].
A single-center, observational, descriptive,
cross-sectional study investigated the effective-
ness and safety/tolerability of ESL in 61 con-
secutive patients with drug-resistant epilepsy
over a mean follow-up duration of 4.7 months
[32]. These included 13 patients who transi-
tioned overnight from CBZ to ESL (CBZ to ESL
ratio, 1:1 to 1:1.3; up to a maximum ESL dose of
1600 mg/day) and 12 patients who transitioned
overnight from OXC to ESL (OXC to ESL ratio,
1:1.1) [32]. Eight of the 13 patients who transi-
tioned from CBZ were followed up for more
than 3 months after initiating ESL and the
median number of seizures/month increased by
33.3% in these patients (p = not significant)
[32]. In contrast, 11 of the 12 patients who
transitioned from OXC were followed up for
more than 3 months and the median number of
seizures/month decreased by 66.7% in these
patients (p = 0.017) [32].
The EARLY-ESLI study was a multicenter,
retrospective, 1-year, observational study con-
ducted in 16 hospitals in Spain, which included
Fig. 2 Responder rates in patients included in the ESL
phase III adjunctive therapy trials who were not receiving
CBZ or who were receiving CBZ. Response was deﬁned as
at least 50% seizure frequency reduction from baseline
[30]. CBZ carbamazepine, ESL eslicarbazepine acetate
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253 patients with focal epilepsy, aged 18 years
or over, in whom ESL treatment was initiated
because of failure with the first AED
monotherapy [33]. The primary reasons for ESL
initiation were lack of efficacy (n = 157) and
tolerability problems (n = 74) with the first AED
monotherapy [33]. A total of 28 patients con-
verted from CBZ monotherapy to ESL
monotherapy at some point during follow-up.
Three of four patients who converted to ESL
because of lack of efficacy with CBZ were seizure
free at 1 year [33]. Similarly, 12 patients con-
verted from OXC monotherapy to ESL
monotherapy, and one of four patients who did
so because of lack of efficacy was seizure free at
1 year [33].
Differences in Effectiveness: Summary
Despite limited direct head-to-head data, ESL
has been shown to be effective as adjunctive
therapy in patients who have previously
achieved inadequate seizure control with CBZ
[30]. This indicates that the use of different
dibenzazepine agents in combination can pro-
vide additive effectiveness benefits, which may
reflect underlying differences in the mecha-
nisms of action of this family of AEDs
[1, 27, 28]. Similarly, this may in part explain
why ESL monotherapy can be effective in
patients who have switched from another
dibenzazepine, such as CBZ or OXC, because of
inadequate efficacy [31–33]. Overall, the evi-
dence outlined here demonstrates that patients
who have not achieved adequate seizure control
with CBZ or OXC may experience improvement
in seizure control with ESL, when used either as
an adjunctive treatment or as monotherapy.
TOLERABILITY PROFILES: DO THESE
DIFFER?
In the phase III trial that compared ESL with
CBZ-CR as monotherapy for patients with
newly diagnosed focal epilepsy, the safety pro-
file of ESL was generally similar to that of CBZ-
CR [29]. The incidence of treatment-emergent
AEs judged to be at least possibly treatment-
related was lower with ESL than with CBZ-CR
(42.1% vs 51.5%), as was the incidence of
treatment-emergent AEs leading to discontinu-
ation (14.0% vs 18.4%) [29]. Fewer patients
treated with ESL versus CBZ-CR experienced
treatment-related increases in gamma-glutamyl
transferase (3.5% vs 13.1%) and alanine
aminotransferase (0.5% vs 2.2%) [29]. In addi-
tion, fewer patients treated with ESL versus
CBZ-CR discontinued because of allergic der-
matitis (0.5% vs 1.7%) [29]. The incidence of
hyponatremia judged to be at least possibly
treatment-related was higher with ESL than
with CBZ-CR (2.5% vs 1.0%), but only one
patient (in the CBZ-CR group) discontinued
because of this AE [29]. In the post hoc analysis
of 1049 patients enrolled in three ESL phase III
adjunctive therapy trials, in which outcomes
were compared between patients who did
(n = 611) and did not (n = 438) receive CBZ as a
concomitant AED, the incidence of treatment-
emergent AEs was higher in patients treated
with CBZ (50% with placebo; 71% with ESL)
than in those who were not treated with CBZ
(40% with placebo; 55% with ESL) [30].
Several real-world clinical practice studies
have investigated the impact on tolerability of
transitioning patients who were experiencing
OXC- or CBZ-related AEs to ESL [31–37]. In a
single-center, retrospective chart review of 23
patients with focal epilepsy who were transi-
tioned overnight from OXC to ESL because of
tolerability problems, an evaluation of the
effects of the transition was made after 1 and
3 months of ESL treatment [34]. The most
intolerable OXC-related AEs were somnolence,
dizziness, and diplopia [34], consistent with the
aforementioned pattern of OXC metabolism
[19]. OXC-related AEs had resolved in 14/23
(60.9%) and 15/23 (65.2%) patients 1 and
3 months after transition, respectively [34].
Two-thirds (66.5%) of OXC-related AEs occur-
red in the morning and 93.4% of these resolved
after transitioning from OXC to ESL [34]. The
only ESL-related AE reported by at least 10% of
patients was headache, and, importantly, all
patients continued ESL treatment throughout
the study period [34].
A retrospective, single-center study was
conducted in which 21 patients with drug-
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resistant focal epilepsy on a stable dose of
immediate-release OXC for at least 4 weeks were
transitioned overnight to ESL because they
experienced persistent seizures with OXC but
were unable to tolerate increased OXC dosing
because of AEs [35]. Tolerability (assessed using
the Adverse Events Profile [AEP]), quality of life
(assessed using the Quality of Life in Epilepsy
Inventory-10 [QOLIE-10]), and alertness (asses-
sed as reaction time using a subtest of the Test
Battery for Attention Performance version 2.3)
were compared immediately before and 5 days
after transitioning from OXC to ESL [35]. Fol-
lowing transition to ESL, there were significant
improvements in mean scores for AEP
(p\ 0.001), QOLIE-10 (p = 0.001), and alertness
(p\ 0.05) [35]. Overall, AEP total scores, QOLIE-
10 total scores, and alertness scores improved
for 100.0%, 81.0%, and 76.2% of patients,
respectively [35]. Serum sodium levels (mea-
sured on days 0 and 5) remained stable, indi-
cating that the likelihood of developing
hyponatremia did not increase after switching
treatment overnight [35].
In a single-center, observational, descriptive,
cross-sectional study of 61 consecutive patients
with drug-resistant epilepsy who were treated
with ESL over a mean follow-up duration of
4.7 months, eight of 13 patients who were
transitioned overnight from CBZ to ESL expe-
rienced AEs, as did four of 12 patients who
transitioned overnight from OXC to ESL, but all
AEs were transient [32]. Two patients who
transitioned from OXC to ESL reported that the
AEs they experienced with OXC (dizziness and
drowsiness) improved after transitioning to ESL
[32]. Overall, decreased sodium levels were
observed in 4/61 (6.6%) patients, none of whom
was taking OXC or CBZ [32]. None of these
sodium values were below 125 mmol/L [32]. In
addition, hyponatremia resolved (from 128 to
138 mmol/L) in one patient and remained the
same (133 mmol/L) in another patient after
transitioning from OXC to ESL [32]. In a mul-
ticenter, retrospective case series of 29 elderly
patients ([65 years) with focal seizures who
were treated with ESL, the tolerability profile
improved in four of five patients who transi-
tioned from CBZ or OXC to ESL because of AEs
[36]. Overall, 3/29 (10.3%) patients developed
hyponatremia, but only one developed symp-
toms (confusion) that resolved after withdrawal
of ESL [36].
In the EARLY-ESLI study, 14 patients con-
verted from CBZ monotherapy to ESL
monotherapy because of tolerability problems
with CBZ, and only two of these patients
reported AEs at 1 year [33]. In addition, of the
five patients converted from OXC monotherapy
to ESL monotherapy because of tolerability
problems with OXC, three had no AEs with ESL
at 1 year [33]. A total of 137 patients withdrew
to ESL monotherapy from treatment with other
AEDs during EARLY-ESLI, of whom three (2.2%)
developed hyponatremia; hyponatremia was
symptomatic in only one of these patients
(113 mEq/L) [33]. In the ESLIBASE study, the
study population included 26 patients who
were transitioned to ESL from OXC because of
OXC-related AEs and 17 patients who transi-
tioned from CBZ because of CBZ-related AEs
[31]. Overall, 15/26 (57.7%) patients previously
treated with OXC no longer had AEs after
transitioning to ESL, and 8/17 (47.1%) previ-
ously treated with CBZ no longer had AEs after
transitioning to ESL [31]. Thus, after transition
from either OXC or CBZ to ESL, approximately
50% of patients no longer experienced AEs. In
the overall ESLIBASE population, hyponatremia
(ranging from 116 to 128 mEq/L) was reported
in 9/327 (2.8%) patients and led to treatment
discontinuation in four patients [31]. Hypona-
tremia was asymptomatic in eight patients; the
remaining patient reported confusion that
resolved rapidly after ESL discontinuation and
did not require hospital admission [31].
Nonadherence to AEDs is a common and
challenging problem in epilepsy, with nonad-
herence rates of up to 60% reported in some
populations [37]. In the EARLY-ESLI study,
adherence improved in all of the 10 patients
who converted from CBZ to ESL monotherapy
because of adherence problems with CBZ [33].
Similarly, of five patients who converted from
OXC monotherapy to ESL monotherapy
because of tolerability problems with OXC,
three had no AEs with ESL at 1 year, and of three
patients who converted because of adherence
problems with OXC, two had no adherence
problems with ESL at 1 year [33].
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Differences Within the Dibenzazepine
Family in Their Impact on Lipid Markers
Treatment with enzyme-inducing AEDs,
including CBZ, has been associated with
increased serum lipid levels [4]. Although (S)-
licarbazepine is a weak inducer of cytochrome
P450 3A4 and uridine 50-diphospho-glucurono-
syltransferase [14], it is a less potent enzyme
inducer than CBZ, which induces a broader
range of oxidative and conjugating enzymes [1].
Lipid profiles are particularly relevant in light of
epidemiological evidence demonstrating that
patients with epilepsy have significantly ele-
vated rates of cardiovascular and cerebrovascu-
lar disease [4]. In a study in which 12 patients
with epilepsy transitioned from CBZ to OXC,
cytochrome P450 enzyme system function
(assessed by evaluating antipyrine pharmacoki-
netics) was shown to normalize after 2 months,
resulting in a significant reduction in serum
total cholesterol levels and a detectable but not
statistically significant reduction in low-density
lipoprotein cholesterol levels (p = 0.057), with
serum concentrations of high-density lipopro-
tein cholesterol and triglycerides remaining
unchanged [38]. Seizure control was generally
similar following the transition from CBZ to
OXC, with only one patient experiencing an
increase in seizure frequency [38]. Two further
studies have specifically investigated the impact
of ESL on patients’ lipid profiles, including the
effect of transitioning from CBZ or OXC to ESL
[39, 40]. A retrospective cohort study of 36 adult
patients assessed lipid levels before and after
initiating ESL as adjunctive therapy over an
average follow-up of 11 months [39]. After at
least 6 months of ESL treatment, there were
significant reductions in the levels of total
cholesterol (from 191.3 to 179.7 mg/dL;
p\0.0001) and low-density lipoprotein
cholesterol (from 114.6 to 103.1 mg/dL;
p\0.0001), and a significant increase in the
level of high-density lipoprotein cholesterol
(from 57.5 to 63.9 mg/dL; p\0.0001) [39]. A
second observational, retrospective, single-cen-
ter, cohort study investigated the impact of ESL
treatment on the lipid profiles of 108 patients
over a median duration of 23.1 months (range
3–41 months) [40]. Of these, 51.9% had
switched to ESL from prior treatment with CBZ
or OXC [40]. In the overall population, mean
total cholesterol levels decreased significantly
from previous pathological ([ 200 mg/dL) to
normal (\200 mg/dL) values during ESL treat-
ment (p = 0.015) [40]. In the subgroup of
patients who transitioned from CBZ or OXC to
ESL, there was a significant decrease in median
triglyceride levels (p\0.001) and mean low-
density lipoprotein cholesterol (p = 0.014), and
a marked decrease in mean total cholesterol
(p = 0.053) [40]. The proportion of patients with
hypercholesterolemia also decreased signifi-
cantly after transitioning to ESL (from 57.1% to
37.5%; p = 0.018), as did the proportion of
patients with hypertriglyceridemia (from 10.8%
to 1.8%; p = 0.011) (Fig. 3) [40]. Both studies
therefore suggest that switching to ESL is of
value when considering lipid profiles.
Fig. 3 Percentage of patients with normal or elevated
levels of total cholesterol and triglycerides before and after
switching treatment from CBZ or OXC to ESL. CBZ
carbamazepine, ESL eslicarbazepine acetate, OXC oxcar-
bazepine. Adapted from Epilepsy Research, 115, M. Ley, A.
Principe, J. Jime´nez-Conde, R. Rocamora, Assessing long-
term effects of eslicarbazepine acetate on lipid metabolism
proﬁle, sodium values and liver function tests,
pp. 147–152, Copyright (2015), with permission from
Elsevier
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Tolerability Differences: Summary
In a phase III monotherapy trial, ESL was shown
to have a generally similar tolerability profile to
CBZ-CR, but with lower incidences of treat-
ment-related AEs and AEs leading to discontin-
uation [29]. In clinical trials of ESL adjunctive
therapy, treatment regimens that included CBZ
were shown to be less well tolerated than those
that did not, despite attaining clinical efficacy
[30]. There is also considerable evidence to
demonstrate that patients transitioning from
OXC or CBZ to ESL because of AEs experience
improvements in tolerability [31–36]. Interest-
ingly, improvements in quality of life and/or
alertness were also reported [35]. Patients tran-
sitioning from OXC or CBZ to ESL have addi-
tionally demonstrated significant
improvements in lipid profiles [40]. Transition-
ing from CBZ or OXC to ESL does not appear to
be associated with an increased likelihood of
developing hyponatremia; however, it is good
practice to monitor for the potential develop-
ment of hyponatremia with all dibenzazepine
agents, particularly in the elderly. Blood level
monitoring is not routinely required for diben-
zazepine AEDs [12–14]. However, decreased
platelet or white blood cell counts may occur
with CBZ treatment and it is therefore recom-
mended that a complete blood count should be
obtained before starting CBZ treatment and
periodically thereafter [12].
CLINICAL IMPLICATIONS
ESL has been shown to be effective in patients
who have previously not achieved adequate
seizure control with CBZ or OXC, when used
instead of these agents. ESL has also been shown
to improve effectiveness when added to CBZ
treatment. Such evidence is consistent with
findings from experimental models that have
revealed differences in the mechanism of action
between dibenzazepine agents [3, 27, 28], sup-
porting the notion of ‘‘rational polytherapy’’,
whereby agents with different mechanisms of
action may synergize when used in combina-
tion to provide enhanced effectiveness [41].
Rational polytherapy must, however, also take
account of the increased risk of adverse effects
and pharmacokinetic interactions as a patient’s
drug burden is increased, and thus balance the
potential benefit of increased effectiveness with
polytherapy against the potential risk of
increased tolerability problems [42]. The co-
administration of more than one AED is likely
to limit dosing of the newly added drug. In
patients who fail first-line monotherapy, and
have started their second monotherapy, there is
evidence to support switching from CBZ or
OXC to ESL. Evidence from clinical practice
studies also demonstrates that there are differ-
ences in tolerability within the dibenzazepine
family, since patients who have experienced
CBZ- or OXC-related AEs may experience
improvements in tolerability when transitioned
to ESL. Furthermore, it may be appropriate to
transition patients from CBZ to ESL if they are
experiencing, or at risk of developing, metabolic
problems resulting from CBZ induction of
enzymes involved in endogenous metabolic
pathways (e.g., hypercholesterolemia, osteo-
porosis, sexual dysfunction) [4, 43, 44]. Pub-
lished guidance has outlined the
methodological considerations associated with
transitioning patients from CBZ or OXC to ESL
[43, 44]. Taken together, and despite the lack of
direct comparative data, current evidence
demonstrates that ESL differs from other
dibenzazepine AEDs, highlighting the impor-
tance of adapting and tailoring treatment to
each patient’s specific needs.
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